Shop Medical Lab Equipment
Abinscience Anti-Human Siglec-3/CD33 Reference Antibody (Lintuzumab, RUO) (HB185026)
Overview
| Catalog No. | HB185026 |
|---|---|
| Description | Abinscience Lintuzumab(HB185026) is a research-grade recombinant antibody targeting CD33. Produced in mammalian cells with native-like glycosylation.
HIGHLIGHTS
|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Human |
| Isotype | IgG1-kappa |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3 |
| Endotoxin level | < 10 EU/mg |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P20138 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | 225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, 166089-32-3 |
| Background | Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg). 1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343
2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212
3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323
4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872
5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109
6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905
7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955
8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798
|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Anti-LASV GPC Recombinant Antibody (Fab 37.7) (VK453013)
Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
Images
Detects CD33 in indirect ELISAs.
SDS-PAGE for Research Grade Lintuzumab.
Datasheets
Anti-Human Siglec-3/CD33 Reference Antibody (Lintuzumab, RUO).pdf